JPRN-UMIN000040175招募中未知
Prospective evaluation of vedolizumab-effects and safety in patients with inflammatory bowel diseases (VED IBD Cohort Study) - VED IBD Cohort Study
Saitama Medical Center, Saitama Medical University0 个研究点目标入组 50 人开始时间: 2020年5月11日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Patients without informed consent 2. Patients determined to be inappropriate by doctor
研究者
相似试验
已完成
不适用
Prospective evaluation of vedolizumab-effects in patients with inflammatory bowel diseasesulcerative colitis and Crohn's diseaseJPRN-UMIN000039916Saitama Medical Center, Saitama Medical University50
撤回
不适用
Efficacy and Safety of vedolizumab in biologic-naïve Korean patients with moderate to severe inflammatory bowel diseaseDiseases of the digestive systemKCT0006087Yonsei University Health System, Severance Hospital60
暂停
不适用
Pharmacokinetics and efficacy of Vedolizumab in inflammatory bowel diseasesulcerative colitis and Crohn's diseaseJPRN-UMIN000045425Shiga University of Medical Science50
已完成
3 期
Phase III Study of MLN0002 (300 mg) in the Treatment of Ulcerative ColitisUlcerative ColitisNCT02039505Takeda292
撤回
3 期
Efficacy and Safety of Vedolizumab Intravenous (IV) in the Treatment of Primary Sclerosing Cholangitis in Subjects With Underlying Inflammatory Bowel DiseasePrimary Sclerosing CholangitisInflammatory Bowel DiseaseNCT03035058Takeda